Private Canadian biotech firm Hyasynth recently announced a US patent award for using yeast to biosynthesize cannabinoids and is the first to sell yeast-derived cannabidiol (CBD) built on this proprietary pathway. The biosynthesis of major and rare cannabinoids provides multiple growth prospects in pharmaceutical and consumer markets. Key catalysts for further funding and expanding the valuation include growing commercial sales in 2022 and demonstrating production of cannabinoids in a large-scale, low-cost manner.
Written by
Hyasynth Biologicals |
Patent for efficient cannabinoid production
|
Biotechnology |
QuickView
21 October 2021 |
Share details
Business description
Bull
Bear
Analyst
|
|||||||||||||||||||||
Private Canadian biotech firm Hyasynth recently announced a US patent award for using yeast to biosynthesize cannabinoids and is the first to sell yeast-derived cannabidiol (CBD) built on this proprietary pathway. The biosynthesis of major and rare cannabinoids provides multiple growth prospects in pharmaceutical and consumer markets. Key catalysts for further funding and expanding the valuation include growing commercial sales in 2022 and demonstrating production of cannabinoids in a large-scale, low-cost manner.
Using yeast to biosynthesize cannabinoids
Hyasynth produces CBD and a range of rare cannabinoids through yeast fermentation without the need for traditional cultivation from cannabis or hemp plants. The company recently announced a US patent on its cannabinoid biosynthesis pathway, which reduces the number of enzymatic yeast steps to produce CBD by 75%. Management believes this makes Hyasynth’s strain significantly more efficient and allows it to engineer new yeast strains rapidly and optimize them for large-scale production. Furthermore, this patent award follows Hyasynth’s 2020 achievement of the first ever sale of CBD produced and extracted from yeast. Importantly, using biosynthesis aids in the precision manufacturing of cannabinoids on a large scale with consistent quality and reliability.
Expanding pharma markets with significant potential
Cannabinoid markets are expanding, especially in the cosmetic and pharmaceutical markets. While still in its infancy, research on using cannabinoids to treat medical conditions is growing, with several candidates in clinical development. For instance, rare cannabinoids could potentially treat conditions such as Crohn’s disease, and companies such as GW Pharmaceuticals have developed treatments for epilepsy. Raymond James estimated that the global market for cannabinoid biosynthesis could reach C$10bn in 2025 and C$115bn by 2040. Biosynthetics have the potential to generate larger amounts of rare cannabinoids than those that occur in small quantities in the plant. To take advantage of these growing markets, Hyasynth’s proprietary strains can be scaled rapidly in production, reducing time to market and potentially enabling sales to begin within months.
Catalysts: Sales milestones and scaling production
As Hyasynth is a private company, financials are not available nor is the stock publicly traded, so appraising its valuation is difficult. Hyasynth expects to be profitable by the end of 2022. The cannabinoid biosynthesis market has received significant funding over the past few years, and a 2019 SynBioBeta report noted that more than 15 companies made multi-million-dollar investments in cannabinoid biosynthesis companies. Key catalysts for further funding and an expanding valuation include moving product to market by growing commercial sales in 2022 and Hyasynth demonstrating that it can scale production from a pilot to a larger commercial level, yet still in a cost-effective manner.
EDISON QUICKVIEWS ARE NORMALLY ONE OFF PUBLICATIONS WITH NO COMMITMENT TO WRITING ANY FOLLOW UP. QUICKVIEW NOTES USE CONSENSUS EARNINGS ESTIMATES.
|
||||||||||||
|
||||||||||||
Research: Industrials
DVS TECHNOLOGY’s H121 results have recovered since last year, which was affected by the COVID-19 pandemic. Operating leverage triggered an improvement in EBITDA margin of 440bp to 7.8%. The order intake was strong with 32% y-o-y growth in the first half and management expects further improvement in H221. The company has maintained its FY21 guidance for revenue growth of 11% but adjusted it for pre-tax profit from €5m to €3–5m, partly due to the expected impact of higher raw material prices and a shortage of components.